Jan 242023

Halberd Agrees to Animal Testing at Mississippi State University

January 24th, 2023|Categories: Investor News, Medical, News, Press Releases|Tags: , , |

College of Veterinary Medicine to conduct testing Jackson Center, PA January 24, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) has agreed to conduct animal testing at Mississippi State University’s (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project.  The project will be investigating the effectiveness of novel therapeutic ...

Jan 32023

Halberd Corporation 2022 Year End CEO Letter and 2023 Goals

January 3rd, 2023|Categories: Featured, Investor News, Press Releases, Update Letter|Tags: , , , |

Profound Advancements Explained Jackson Center, PA, January 3, 2023 -- Halberd Corporation (OTC: HALB) The second half of 2022 was a very busy time. 2022 2nd HALF ACHIEVEMENTS Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. Halberd formed a Cancer Therapeutics Subsidiary, Halberd Cancer Therapeutics, LTD, to allow cancer treatment research to continue in parallel and ...

Dec 62022

Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication

December 6th, 2022|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , |

Halberd’s method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. Jackson Center, PA December 6, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB).  Halberd will utilize its laser eradication technology which successfully  eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release.  Gram-negative bacteria ...

Dec 52022

“The Street Podcast” Features Halberd’s “Groundbreaking” Cancer Treatment Approach. Listen Now!

December 5th, 2022|Categories: Featured, Investor News, Medical, News|Tags: , , , , , , |

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd’s patented methodology for Cancer Antigen Eradication Treatment. Jackson Center, PA December 5, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully eradicating Cancer disease antigens”. Listen here: Dr. Mitchell S. Felder, Halberd’s Chief Technology Officer and a board-certified attending neurologist ...

Nov 302022

Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant

November 30th, 2022|Categories: Featured, Investor News, Medical, News|Tags: , , , , |

UPDATED. Boosts effectiveness by 44.4%% of commercially available Covid antibody in cocktail Jackson Center, PA November 30, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.”  The article has been peer reviewed and accepted for publication, but has not yet been published. The paper describes the Halberd sponsored research which resulted ...

Nov 172022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint By Eradicating Cancer Disease Antigen Linked to Breast Cancer

November 17th, 2022|Categories: Featured, Investor News, Medical, News|Tags: , , , , , , |

Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date Jackson Center, PA, November 17, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in their latest series of tests.  Halberd had been successful previously in eradicating all five cancer disease antigens (PD-1, PDL-1, IL-6, ...

Go to Top